After a long wait, the FDA has OK’d Novartis’s Gilenya as a first-line treatment for relapsing forms of multiple sclerosis — the disease’s most common form. MS affects over 400,000 Americans and more than 2.1 million people worldwide, giving Gilenya blockbuster potential.
Continue reading Novartis’s Multiple Sclerosis Pill, a Likely Blockbuster, Gets FDA Approval
Novartis’s Multiple Sclerosis Pill, a Likely Blockbuster, Gets FDA Approval originally appeared on DailyFinance on Wed, 22 Sep 2010 09:30:00.
Filed Under: Company News, Investing, Health Care, Novartis